Dynavax Technologies Corporation (DVAX)
| Market Cap | 1.27B |
| Revenue (ttm) | 330.51M |
| Net Income (ttm) | -43.40M |
| Shares Out | 117.42M |
| EPS (ttm) | -0.36 |
| PE Ratio | n/a |
| Forward PE | 17.47 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,216,713 |
| Open | 10.98 |
| Previous Close | 10.99 |
| Day's Range | 10.52 - 11.06 |
| 52-Week Range | 9.20 - 14.63 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 26.50 (+144.69%) |
| Earnings Date | Nov 5, 2025 |
About DVAX
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for DVAX stock is "Buy." The 12-month stock price target is $26.5, which is an increase of 144.69% from the latest price.
News
Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript
Dynavax Technologies Corporation ( DVAX) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Paul Cox - VP of Investor Relations & Corporate Communications Ryan Spencer - CEO & Di...
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
HEPLISAV-B® quarterly net product revenue of $90 million, a 13% YoY increase; r eiterates full year 2025 HEPLISAV-B® net product revenue guidance range of $315 to $325 million Board of Directors autho...
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Collaboration positioned to leverage Vaxart's oral vaccine platform and Dynavax's commercial experience to address the long-term need for easily administered COVID-19 vaccine options Vaxart to continu...
Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025
EMERYVILLE, Calif. , Oct. 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...
Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial
Z-1018 demonstrates comparable antibody and CD4+ T-cell responses to Shingrix® with a favorable tolerability profile Newly presented data outline robust polyfunctional CD4+ T-cell responses in Z-1018 ...
3 Of My Favorite Biotech Stocks Under $10
Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited ...
Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference
EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, tod...
Dynavax's shingles vaccine shows similar immune response to GSK's shot in study
Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-s...
Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile
At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection...
Dynavax Technologies: A Dip To Accumulate
Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and ...
Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript
Dynavax Technologies Corporation (NASDAQ:DVAX) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Sen...
Dynavax Reports Second Quarter 2025 Financial Results
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, fr...
Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
EMERYVILLE, Calif. , July 29, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, wil...
Dynavax elects all four of its nominees after Deep Track proxy fight
Biopharmaceutical company Dynavax Technologies on Wednesday defeated investment firm Deep Track Capital's effort to unseat directors when investors re-elected all four candidates, the company said.
Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting
EMERYVILLE, Calif. , June 11, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commerciali...
Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting
Dynavax's Strategy is Delivering Significant Long-Term Stockholder Value Dynavax's Nominees Are Vastly Superior to Deep Track's Candidates Across Every Critical Area Follow Recommendations of Proxy Ad...
Dynavax Comments on Glass Lewis Recommendation
Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best In...
Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
Dynavax to Present at William Blair's 45th Annual Growth Stock Conference
EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, toda...
Deep Track Capital Comments on ISS Recommendation
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...
ISS backs Dynavax directors in board fight with Deep Track Capital
Proxy advisory firm Institutional Shareholder Services urged Dynavax Technologies shareholders on Friday to reelect all its company directors instead of backing life sciences investment firm Deep Trac...
Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees
ISS Recognizes There is No Case for Change Dynavax's Superior Strategy and Current Board are Best Equipped to Deliver Significant Long-Term Stockholder Value Dynavax Comments on Deep Track's Misleadin...
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good
Dynavax Technologies' stock has dropped 25% since my last 'Hold' rating in February 2025. The company's HEPLISAV-B continues to grow at significant rates. DVAX has ample liquidity supporting a balance...
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dy...